MedTrace Logo

Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure

NCT00259038 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2016-11-08

No results posted yet for this study

Summary

The study will evaluate the safety and efficacy of intravenous infusion of carperitide using pressure measurements inside the heart and great vessels and measuring carperitide concentration in the blood.

Conditions

  • Heart Failure, Congestive
  • Heart Decompensation
  • Left Ventricular Failure
  • Myocardiopathies
  • Systolic or Diastolic Left Ventricular Dysfunction

Interventions

DRUG

Carperitide

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Biljana Pavlovic-Surjancev, MD, PhD · Astellas Pharma US, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2006-02-28
Completion
2006-02-28

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00259038 on ClinicalTrials.gov